HawkInsight

  • Contact Us
  • App
  • English

Nurix Therapeutics GAAP EPS of -$0.67 beats by $0.05, revenue of $12.6M misses by $2.04M

Nurix Therapeutics press release (NASDAQ:NRIX): Q3 GAAP EPS of -$0.67 beats by $0.05.Revenue of $12.6M (-31.8% Y/Y) misses by $2.04M.Cash, cash equivalents and marketable securities was $457.5 million as of August 31, 2024, compared to $452.5 million as of May 31, 2024.

Disclaimer: The views in this article are from the original author and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.

NewFlashHawk Insight
More